Cargando…
Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
PURPOSE: In vivo Alzheimer’s disease (AD) biomarkers for tau pathology are cerebrospinal fluid (CSF) phosphorylated tau (p-tau) and [(18)F]flortaucipir positron emission tomography (PET). Our aim was to assess associations between CSF p-tau with [(18)F]flortaucipir PET and the associations of both t...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567681/ https://www.ncbi.nlm.nih.gov/pubmed/32291510 http://dx.doi.org/10.1007/s00259-020-04758-2 |
_version_ | 1783596377439207424 |
---|---|
author | Wolters, Emma E. Ossenkoppele, Rik Verfaillie, Sander C. J. Coomans, Emma M. Timmers, Tessa Visser, Denise Tuncel, Hayel Golla, Sandeep S. V. Windhorst, Albert D. Boellaard, Ronald van der Flier, Wiesje M. Teunissen, Charlotte E. Scheltens, Philip van Berckel, Bart N. M. |
author_facet | Wolters, Emma E. Ossenkoppele, Rik Verfaillie, Sander C. J. Coomans, Emma M. Timmers, Tessa Visser, Denise Tuncel, Hayel Golla, Sandeep S. V. Windhorst, Albert D. Boellaard, Ronald van der Flier, Wiesje M. Teunissen, Charlotte E. Scheltens, Philip van Berckel, Bart N. M. |
author_sort | Wolters, Emma E. |
collection | PubMed |
description | PURPOSE: In vivo Alzheimer’s disease (AD) biomarkers for tau pathology are cerebrospinal fluid (CSF) phosphorylated tau (p-tau) and [(18)F]flortaucipir positron emission tomography (PET). Our aim was to assess associations between CSF p-tau with [(18)F]flortaucipir PET and the associations of both tau biomarkers with cognition and atrophy. METHODS: We included 78 amyloid positive cognitively impaired patients (clinical diagnoses mild cognitive impairment (MCI, n = 8) and AD dementia (n = 45) and 25 cognitively normal subjects with subjective cognitive decline (SCD) (40% amyloid-positive)). Dynamic 130 min [(18)F]flortaucipir PET scans were acquired to generate binding potential (BP(ND)) images using receptor parametric mapping and standardized uptake values ratios of 80–100 min (SUVr(80-100min)) post injection. We obtained regional BP(ND) and SUVr from entorhinal, limbic, and neocortical regions-of-interest (ROIs), closely aligning to the neuropathological tau staging schemes. Cognition was assessed using MMSE and composite scores of four cognitive domains, and atrophy was measured using gray matter volume covering the major brain lobes. First, we used linear regressions to investigate associations between CSF p-tau (independent variable) and tau PET (dependent variable). Second, we used linear regressions to investigate associations between CSF p-tau, tau PET (separate independent variables, model 1), and cognition (dependent variable). We then assessed the independent effects of CSF p-tau and tau PET on cognition by simultaneously adding the other tau biomarker as a predictor (model 2). Finally, we performed the same procedure for model 1 and 2, but replaced cognition with atrophy. Models were adjusted for age, sex, time lag between assessments, education (cognition only), and total intracranial volume (atrophy only). RESULTS: Higher [(18)F]flortaucipir BP(ND) was associated with higher CSF p-tau (range of standardized betas (sβ) across ROIs, 0.43–0.46; all p < 0.01). [(18)F]flortaucipir BP(ND) was more strongly associated with cognition and atrophy than CSF p-tau. When [(18)F]flortaucipir BP(ND) and CSF p-tau were entered simultaneously, [(18)F]flortaucipir BP(ND) (range sβ = − 0.20 to – 0.57, all p < 0.05) was strongly associated with multiple cognitive domains and atrophy regions. SUVr showed comparable results to BP(ND). CONCLUSION: Regional [(18)F]flortaucipir BP(ND) correlated stronger with cognition and neurodegeneration than CSF p-tau, suggesting that tau PET more accurately reflects disease severity in AD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-020-04758-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7567681 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-75676812020-10-19 Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease Wolters, Emma E. Ossenkoppele, Rik Verfaillie, Sander C. J. Coomans, Emma M. Timmers, Tessa Visser, Denise Tuncel, Hayel Golla, Sandeep S. V. Windhorst, Albert D. Boellaard, Ronald van der Flier, Wiesje M. Teunissen, Charlotte E. Scheltens, Philip van Berckel, Bart N. M. Eur J Nucl Med Mol Imaging Original Article PURPOSE: In vivo Alzheimer’s disease (AD) biomarkers for tau pathology are cerebrospinal fluid (CSF) phosphorylated tau (p-tau) and [(18)F]flortaucipir positron emission tomography (PET). Our aim was to assess associations between CSF p-tau with [(18)F]flortaucipir PET and the associations of both tau biomarkers with cognition and atrophy. METHODS: We included 78 amyloid positive cognitively impaired patients (clinical diagnoses mild cognitive impairment (MCI, n = 8) and AD dementia (n = 45) and 25 cognitively normal subjects with subjective cognitive decline (SCD) (40% amyloid-positive)). Dynamic 130 min [(18)F]flortaucipir PET scans were acquired to generate binding potential (BP(ND)) images using receptor parametric mapping and standardized uptake values ratios of 80–100 min (SUVr(80-100min)) post injection. We obtained regional BP(ND) and SUVr from entorhinal, limbic, and neocortical regions-of-interest (ROIs), closely aligning to the neuropathological tau staging schemes. Cognition was assessed using MMSE and composite scores of four cognitive domains, and atrophy was measured using gray matter volume covering the major brain lobes. First, we used linear regressions to investigate associations between CSF p-tau (independent variable) and tau PET (dependent variable). Second, we used linear regressions to investigate associations between CSF p-tau, tau PET (separate independent variables, model 1), and cognition (dependent variable). We then assessed the independent effects of CSF p-tau and tau PET on cognition by simultaneously adding the other tau biomarker as a predictor (model 2). Finally, we performed the same procedure for model 1 and 2, but replaced cognition with atrophy. Models were adjusted for age, sex, time lag between assessments, education (cognition only), and total intracranial volume (atrophy only). RESULTS: Higher [(18)F]flortaucipir BP(ND) was associated with higher CSF p-tau (range of standardized betas (sβ) across ROIs, 0.43–0.46; all p < 0.01). [(18)F]flortaucipir BP(ND) was more strongly associated with cognition and atrophy than CSF p-tau. When [(18)F]flortaucipir BP(ND) and CSF p-tau were entered simultaneously, [(18)F]flortaucipir BP(ND) (range sβ = − 0.20 to – 0.57, all p < 0.05) was strongly associated with multiple cognitive domains and atrophy regions. SUVr showed comparable results to BP(ND). CONCLUSION: Regional [(18)F]flortaucipir BP(ND) correlated stronger with cognition and neurodegeneration than CSF p-tau, suggesting that tau PET more accurately reflects disease severity in AD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-020-04758-2) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-04-14 2020 /pmc/articles/PMC7567681/ /pubmed/32291510 http://dx.doi.org/10.1007/s00259-020-04758-2 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Wolters, Emma E. Ossenkoppele, Rik Verfaillie, Sander C. J. Coomans, Emma M. Timmers, Tessa Visser, Denise Tuncel, Hayel Golla, Sandeep S. V. Windhorst, Albert D. Boellaard, Ronald van der Flier, Wiesje M. Teunissen, Charlotte E. Scheltens, Philip van Berckel, Bart N. M. Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease |
title | Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease |
title_full | Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease |
title_fullStr | Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease |
title_full_unstemmed | Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease |
title_short | Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease |
title_sort | regional [(18)f]flortaucipir pet is more closely associated with disease severity than csf p-tau in alzheimer’s disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567681/ https://www.ncbi.nlm.nih.gov/pubmed/32291510 http://dx.doi.org/10.1007/s00259-020-04758-2 |
work_keys_str_mv | AT woltersemmae regional18fflortaucipirpetismorecloselyassociatedwithdiseaseseveritythancsfptauinalzheimersdisease AT ossenkoppelerik regional18fflortaucipirpetismorecloselyassociatedwithdiseaseseveritythancsfptauinalzheimersdisease AT verfailliesandercj regional18fflortaucipirpetismorecloselyassociatedwithdiseaseseveritythancsfptauinalzheimersdisease AT coomansemmam regional18fflortaucipirpetismorecloselyassociatedwithdiseaseseveritythancsfptauinalzheimersdisease AT timmerstessa regional18fflortaucipirpetismorecloselyassociatedwithdiseaseseveritythancsfptauinalzheimersdisease AT visserdenise regional18fflortaucipirpetismorecloselyassociatedwithdiseaseseveritythancsfptauinalzheimersdisease AT tuncelhayel regional18fflortaucipirpetismorecloselyassociatedwithdiseaseseveritythancsfptauinalzheimersdisease AT gollasandeepsv regional18fflortaucipirpetismorecloselyassociatedwithdiseaseseveritythancsfptauinalzheimersdisease AT windhorstalbertd regional18fflortaucipirpetismorecloselyassociatedwithdiseaseseveritythancsfptauinalzheimersdisease AT boellaardronald regional18fflortaucipirpetismorecloselyassociatedwithdiseaseseveritythancsfptauinalzheimersdisease AT vanderflierwiesjem regional18fflortaucipirpetismorecloselyassociatedwithdiseaseseveritythancsfptauinalzheimersdisease AT teunissencharlottee regional18fflortaucipirpetismorecloselyassociatedwithdiseaseseveritythancsfptauinalzheimersdisease AT scheltensphilip regional18fflortaucipirpetismorecloselyassociatedwithdiseaseseveritythancsfptauinalzheimersdisease AT vanberckelbartnm regional18fflortaucipirpetismorecloselyassociatedwithdiseaseseveritythancsfptauinalzheimersdisease |